Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million – STAT

Complete your personal information for a more tailored experience
Home
Don’t miss outSubscribe to STAT+ today, for the best life sciences journalism in the industry
By Jason Mast Feb. 21, 2025
General Assignment Reporter Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered biotech avoid bankruptcy.Bluebird shareholders will receive around $3 per share but can obtain another $6.87 per share in a contingent value right, or CVR, if Bluebird’s portfolio of therapies start to become commercially successful, bringing in at least $600 million per year by 2027.advertisementThe company had entered Friday with a market cap of $68.4 million and was increasingly in danger of simply running out of cash.STAT+ Exclusive StoryAlready have an account? Log inAlready have an account? Log inMonthly$39Totals $468 per yearTotals $468 per yearStarter$30for 3 months, then $399/yearThen $399/yearAnnual$399Save 15%Save 15%11+ UsersCustomSavings start at 25%!Savings start at 25%!2-10 Users$300Annually per user$300 Annually per user
To read the rest of this story subscribe to STAT+. Jason MastGeneral Assignment ReporterJason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason on Signal at Jasonmast05.Understand how science, health policy, and medicine shape the world every day
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.

By Meghana Keshavan
By Elaine Chen advertisement
By Brittany Trang and Jonathan Wosen
By Elaine Chen
By Adam Feuerstein
By Adam Feuerstein
By Helen Branswell
By Brittany Trang
By Lizzy Lawrence
By Sarah Owermohle and Lev Facher Share optionsXBlueskyLinkedInFacebookDoximityCopy linkReprintsReporting from the frontiers of health and medicineCompanyAccountMore

Source: https://www.statnews.com/2025/02/21/bluebird-bio-sells-itself-to-carlyle-sk-capital-for-less-than-30-million/